16 October 2017 - Twenty-six-year-old Sydney engineering student Igor Mileusnic is a strapping picture of health. Two years ago he was on death’s door.
He was diagnosed with Ewing’s sarcoma, a rare form of bone cancer.
Course after course of chemotherapy failed, then his doctor suggested immunotherapy.
A new report - The New Wave of Immunotherapy Cancer Medicines: The Untapped Potential for Australians - by Deloitte Access Economics, released today and sponsored by pharmaceutical giant MSD, claims at least 7500 Australians could be saved from imminent death from cancer each year if a highly-effective therapy became standard.